The incidence rate grows 17 points to 230 cases per 100,000 inhabitants with six communities at extreme risk

Spain has registered a new rise in incidence to 14 days after the weekend, with 230.54 cases per 100,000 inhabitants. This is a significant rise of almost 17 points compared to Friday. The incidence increases in 13 communities and Andalusia, Aragon, Catalonia, Madrid, Euskadi and Navarra are at very high risk of contagion, above 250 cases.

The Ministry of Health has reported 21,071 new cases, slightly less than the previous weekend when 22,744 infections were registered. In total, since the pandemic began, more than a year ago, 3,428,354 people have been infected.

Infections are rising especially in Andalusia, with 4,205 infected people notified since Friday, Madrid (2,541), Catalonia (2,172) and Euskadi (1,005).

During the weekend there have also been 121 new deaths, which leaves the total balance of deaths from COVID-19 at 77,102.

Regarding hospitalizations, 22.4% of ICU beds are occupied by coronavirus patients, a percentage that rises slightly compared to Friday. In total, there are 2,276 COVID patients in intensive care and 10,447 hospitalized for coronavirus.

On the other hand, the communities have administered 12,853,599 doses of the available vaccines against COVID-19 and have already inoculated the first injection to almost 20% of the population (19.9%), close to 9.5 million people. In addition, 7.2% already have the complete guideline, more than 3.4 million people, which leaves Spain very close to the goal of vaccinating more people with double doses than the total number of people infected by coronavirus since the beginning pandemic.

By age group, 98.6% of those over 80 years of age have already received the first puncture and more than 60% have received the complete schedule necessary to obtain immunization with the available vaccines (Pfizer-BioNTech, AstraZeneca and Moderna) , more than 1.7 million people.

These data arrive on the same day that the Carlos III Health Institute, dependent on the Ministry of Science and Health, has announced that it is going to launch a clinical trial in which the efficacy of administering a dose of a vaccine will be observed. against COVID-19 messenger RNA technology, from Pfizer, to people who have already been administered a dose of AstraZeneca.

The announcement comes almost two weeks after Health suspended the administration of AstraZeneca to children under 60 years after a few cases of thrombi were detected in Europe among the millions of vaccinated. The minister had been saying for days that her ministry is studying options on what to do with people of those ages who have already received a dose. Options included giving them another vaccine and delaying the second injection.

The second guideline has to start in May, 3 months after the first people were vaccinated. There are approximately two million people under the age of 60, professionals considered essential, who were vaccinated with AstraZeneca between February and early April. All those who have not passed COVID-19 recently expected a second guideline.


Source link